Sparfloxacinの抗酸菌感染症治療薬としての可能性
スポンサーリンク
概要
- 論文の詳細を見る
We studied the therapeutic potential of utilizing sparfloxacin (SPFX), a newly developed quinolone, to prevent various mycobacterial infections. The in vitro activity of SPFX as a preventive agent for various mycobacteria was determined using the actual countmethod on Ogawa egg medium. The minimal inhibitory concentrations (MIC<SUB>s</SUB>) of SPFXwere as follows: of loxacin-sensitive M. tuberculosis, 0.16-0332μEg/ml; ofloxacin- resistant M. tuberculosis, 0.63-2.5μEg/ml; M. avium; 0.63-10μEg/ml (MICs were equalor less than 1.25μEg/ml in seven out of 11 strains); M. intracellulare, 2.5-10μEg/ml (MICswere equal or more than 10μ/ml in 17 out of 23 strains); M. kansasii, ≥0.08μg/ml; M. chelonae subsp. abscessus, 1.25μg/ml; M. chelonaesubsp. chelonae, 0.63μg/ml; M. scrofulaceum, μg/ml; M. nonchromogenicum, 1.25μg/ml; M. xenopi, ≥0.08μ/ml; M. gordonae, ≥0.08μg/ml. The average serumconcentrations of SPFX during the period of multiple oral administration (200 mg once aday) were 0.35±0.16μg/ml before administration, 0.67±0.32μg/ml after one hour, 1.13±0.21μEg/ml after two hours, 1.27±0.32μg/ml after four hours and 1.31±0.34μg/ml aftersix hours. These results indicate that SPFX has a strong therapeutic potential to preventinfections due to M. tuberculosis, M. kansasii, M. fortuitum, M. chelonae subsp. chelonae, M. scrofulaceum, M.xenopi and M. gordonae. Moreover, it may be expected to be apromising agent against infections due to ofloxacin-resistant M. tuberculosis, M. aviumand M. nonchromogenicum
論文 | ランダム
- 気象研地域気候モデルによる温暖化時の日本域の気候変化予測実験1. 冬
- 気候モデルを用いた大気中CO_2濃度の変動と大気-植生相互作用の関係に関する数値実験
- 各種内科疾患におけるThorn's test
- 2042 リカレント型構造物の耐震設計に関する研究(構造)
- 21174 リカレント耐震設計 : II. リカレント単位モデル化フレームの応答性状と固有周期